Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.62 |
| ▸ | CTSS | P25774 | 2/20 | 0.62 |
| ▸ | CTSK | P43235 | 2/20 | 0.62 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25003863 | 0.87 | LMNA (0.62) | CTSLCTSSCTSKNPC1RAB9A | |
| SCHEMBL15672301 | 0.86 | CA2 (0.77) | — | |
| SCHEMBL11119630 | 0.85 | CTSL (0.56) | CTSLCTSSCTSKPSMB5ACE | |
| SCHEMBL11119626 | 0.85 | CTSL (0.56) | CTSLCTSSCTSKPSMB5ACE | |
| SCHEMBL10668661 | 0.85 | CTSL (0.56) | CTSLCTSSCTSKPSMB5ACE | |
| SCHEMBL8056323 | 0.84 | CTSL (0.58) | CTSLCTSSCTSKPSMB5ACE | |
| SCHEMBL10736522 | 0.84 | CTSL (0.59) | CTSLCTSSCTSKPSMB5ACE | |
| SCHEMBL7852408 | 0.84 | CTSS (0.60) | CTSSCTSKCTRB1NPC1RAB9A | |
| SCHEMBL12537239 | 0.84 | CTSS (0.60) | CTSSCTSKCTRB1NPC1RAB9A | |
| SCHEMBL16523134 | 0.84 | CTSL (0.65) | CTSLCTSSCTSKPSMB5ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045142-A1 | SMALL MOLECULE RPN13 INHIBITORS WITH ANTITUMOR PROPERTIES | MRPS23, RPP30, RPS19 | CTSL 3088/4885CTSS 1200/4885CTSK 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.